BRIEF-Quince Therapeutics Announces The Lancet Neurology Publication Of Phase 3 ATTeST Clinical Trial Data Evaluating Erydex

Reuters08-15

Aug 15 (Reuters) - Quince Therapeutics Inc :

* QUINCE THERAPEUTICS ANNOUNCES THE LANCET NEUROLOGY PUBLICATION OF PHASE 3 ATTEST CLINICAL TRIAL DATA EVALUATING ERYDEX FOR THE TREATMENT OF ATAXIA-TELANGIECTASIA (A-T)

* QUINCE THERAPEUTICS: EXPECTS TO REPORT TOPLINE RESULTS IN Q4 OF 2025

* QUINCE THERAPEUTICS: EXPECTS POTENTIAL NDA SUBMISSION TO FDA & MARKETING AUTHORIZATION APPLICATION SUBMISSION TO EMA IN 2026

Source text for Eikon: Further company coverage:

(Reuters.Briefs@thomsonreuters.com)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2459744762?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-08-15 19:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2459744762","market":"us","top_or_hot":-1,"title":"BRIEF-Quince Therapeutics Announces The Lancet Neurology Publication Of Phase 3 ATTeST Clinical Trial Data Evaluating Erydex","media":"Reuters","content":"<html><body><p>Aug 15 (Reuters) - Quince <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc   :</p><p>   * QUINCE THERAPEUTICS ANNOUNCES THE LANCET NEUROLOGY PUBLICATION OF PHASE 3 ATTEST CLINICAL TRIAL DATA EVALUATING ERYDEX FOR THE TREATMENT OF ATAXIA-TELANGIECTASIA (A-T)</p><p>   * QUINCE THERAPEUTICS: EXPECTS TO REPORT TOPLINE RESULTS IN Q4 OF 2025</p><p>   * QUINCE THERAPEUTICS: EXPECTS POTENTIAL NDA SUBMISSION TO FDA &amp; MARKETING AUTHORIZATION APPLICATION SUBMISSION TO EMA IN 2026</p><p>Source text for Eikon:    Further company coverage:   </p><p> (Reuters.Briefs@thomsonreuters.com)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Quince Therapeutics Announces The Lancet Neurology Publication Of Phase 3 ATTeST Clinical Trial Data Evaluating Erydex</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Quince Therapeutics Announces The Lancet Neurology Publication Of Phase 3 ATTeST Clinical Trial Data Evaluating Erydex\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-08-15 19:04 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Aug 15 (Reuters) - Quince Therapeutics Inc   :   * QUINCE THERAPEUTICS ANNOUNCES THE LANCET NEUROLOGY PUBLICATION OF PHASE 3 ATTEST CLINICAL TRIAL DATA EVALUATING ERYDEX FOR THE TREATMENT OF ATAXIA-...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LENZ","symbol_name":"Therapeutics","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2459744762","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2459744762","pubTimestamp":1723719852,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"Aug 15  - Quince Therapeutics Inc   :   * QUINCE THERAPEUTICS ANNOUNCES THE LANCET NEUROLOGY PUBLICATION OF PHASE 3 ATTEST CLINICAL TRIAL DATA EVALUATING ERYDEX FOR THE TREATMENT OF ATAXIA-TELANGIECTASIA (A-T)   * QUINCE THERAPEUTICS: EXPECTS TO REPORT TOPLINE RESULTS IN Q4 OF 2025   * QUINCE THERAPEUTICS: EXPECTS POTENTIAL NDA SUBMISSION TO FDA & MARKETING AUTHORIZATION APPLICATION SUBMISSION TO EMA IN 2026Source text for Eikon:    Further company coverage:    ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LENZ":"Therapeutics","QNCX":"Quince Therapeutics, Inc.","BK4139":"生物科技"},"translate_title":"BRIEF-Quince Therapeutics宣布《柳叶刀神经病学》发表评估Erydex的3期ATTeST临床试验数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1,"QNCX":0.9},"content_text":"Aug 15 (Reuters) - Quince Therapeutics Inc   :   * QUINCE THERAPEUTICS ANNOUNCES THE LANCET NEUROLOGY PUBLICATION OF PHASE 3 ATTEST CLINICAL TRIAL DATA EVALUATING ERYDEX FOR THE TREATMENT OF ATAXIA-TELANGIECTASIA (A-T)   * QUINCE THERAPEUTICS: EXPECTS TO REPORT TOPLINE RESULTS IN Q4 OF 2025   * QUINCE THERAPEUTICS: EXPECTS POTENTIAL NDA SUBMISSION TO FDA & MARKETING AUTHORIZATION APPLICATION SUBMISSION TO EMA IN 2026Source text for Eikon:    Further company coverage:    (Reuters.Briefs@thomsonreuters.com)","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2459744762"}